ArticleClinical pharmacokinetics2026
Advancing Precision Dosing of 5-FU: Population PK Model Development, Limited Sampling Strategies, and Fit-for-Use Application.
Article in Clinical pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Comparative efficacy and safety of pharmacokinetically guided and body surface area-based 5-fluorouracil dosing in colorectal cancer: a systematic review and meta-analysis.European journal of clinical pharmacology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA significant proportion of patients receiving 5-fluorouracil-based chemotherapy have been reported to experience grade ≥ 3 toxicities, which range from 21 to 76% depending on the treatment regimen. This may in part be due to interpatient variability in pharmacokinetics. More recently, only about 20% of the patients were reported to achieve the target area under the concentration-time curve from time zero to infinity of 20-30 mg*h/L.
objectiveWe aimed to evaluate existing population pharmacokinetic models and develop a final pharmacokinetic model. In addition, we aimed to identify optimal limited sampling strategies to accurately estimate individual area under the concentration-time curve from time zero to infinity, facilitating model-informed precision dosing using a fit-for-use application.
methodsPatient data from four prospective clinical studies were obtained. Published 5-fluorouracil population pharmacokinetic models were evaluated. A final model was developed, and limited sampling strategies were identified. A user-friendly model-informed precision dosing application was created for initial and subsequent dose adjustments.
resultsUsing the published models, population predictions resulted in underestimation of observed concentrations and misspecification of a 24-h infusion regimen were observed, with the two-compartment Michaelis-Menten model outperforming the other model structures. Of this model, the parameters were re-estimated and covariates analysis was conducted. Body surface area significantly influenced the maximum rate of reaction and was implemented using allometric scaling with an exponent of 1.14 (relative standard error 24%). For a bolus in combination with a 46-h continuous infusion, the best limited sampling strategy was T = 0.1 (end of bolus), 1 and 3 h after treatment initiation; while for the 46-h continuous infusion, the optimal limited sampling strategy was T = 0.8, 2, and 5 h. Model-informed precision dosing algorithms were implemented in an model-informed precision dosing application.
conclusionsThe external evaluation of 5-fluorouracil population pharmacokinetic models against a pooled prospective population resulted in a generic two-compartment Michaelis-Menten pharmacokinetic model with body surface area as a covariate on the maximum rate of reaction. The limited sampling strategy and the shiny model-informed precision dosing application demonstrated the potential for accurate dose individualization of 5-fluorouracil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.